Dimerix (DXB) H2 2025 earnings summary

Executive summary

• Achieved strong growth through strategic execution, highlighted by major licensing deals for lead drug candidate DMX-200 (QYTOVRA®) in the US and Japan, with total potential deal value up to AU$1.4 billion and over AU$65 million in payments received to date.

• Advanced the pivotal ACTION3 Phase 3 clinical trial for FSGS, with over 190 global sites activated and key regulatory milestones achieved, including FDA confirmation of proteinuria as an acceptable endpoint for US approval.

• Expanded global partnerships, admitted to the S&P ASX All Ordinaries, and received industry recognition for excellence.

Financial highlights

• Reported total revenue of $5.6 million (up from $0.4 million), primarily from license income and milestone payments, with $4.3 million from a Japanese development milestone.

• Net loss after tax reduced to $13.3 million from $17.1 million year-over-year, despite increased R&D and business development expenses.

• Cash reserves increased to $68.3 million (from $22.1 million), supporting ongoing operations and development.

• R&D expenditure rose 29% to $27.3 million, reflecting intensified clinical and development activity.

Outlook and guidance

• Plans to complete full recruitment of 286 adult patients in the ACTION3 trial in FY26, with potential for accelerated or conditional marketing applications depending on interim data and regulatory feedback.

• Additional pipeline opportunities and licensing partnerships targeted for FY26, with potential for further milestone payments.

• Continued focus on advancing the pipeline, expanding global partnerships, and delivering long-term value.